Bactify from Zynnon facilitates rapid detection of bloodstream infections

(CONNECT) Zynnon AG, the life sciences firm based in Schindellegi in the Swiss canton of Schwyz, has announced the market launch of its new diagnostic platform Bactify. According to a press release, Bactify shortens the time required to detect microbial pathogens from positive blood cultures from days to just a matter of hours. The new system is set to be showcased by Zynnon at the MEDICA 2025 trade fair, which is taking place November 17-20 in Düsseldorf.

Conventional culture-based diagnostic methods, which are carried out manually, can take up to 72 hours and are said to be particularly expensive for laboratories in low and middle-income countries. In turn, this leads to delays in starting targeted therapy and increases the risk for patients. Bactify aims to solve this problem by allowing laboratories with limited resources to perform cost-effective, semi-automated analysis of blood cultures while simultaneously reducing the time to a positive result.

Bactify was developed with Zynnon’s proprietary gas microfluidics technology, which cost-effectively replicates the performance of a gas chromatography system and offers optimized pathogen detection on the basis of Artificial Intelligence. “Bactify represents a major step forward in infection diagnostics”, comments Khaled Abousaleh, CEO of Zynnon. “We’re excited to bring this innovation to MEDICA and share how it can empower laboratories and healthcare providers to deliver faster, more cost-effective care”, he adds. ce/nta